SciELO - Scientific Electronic Library Online

 
vol.11 issue6Self monitoring of blood glucose as a predictor of glycated hemoglobin author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Medifam

Print version ISSN 1131-5768

Abstract

CALVO ROMERO, J. Mª.  and  LIMA RODRIGUEZ, E. Mª.. Repaglinide, a new oral antidiabetic agent . Medifam [online]. 2001, vol.11, n.6, pp.27-30. ISSN 1131-5768.

The arsenal of oral agents with usefulness in the treatment of type 2 diabetes mellitus has been extended in the last few years. Repaglinide is the first of a new class of oral antidiabetic agents that are benzoic acid derivatives, which is a nonsulfonylurea insulin secretagogue. Repaglinide improves the prandial glucose regulation, restoring the diminished and delayed insulin secretion related with the meals in type 2 diabetic patients. When used as monotherapy, the decreases in fasting plasma glucose and glycosylated hemoglobin is similar to those observed with sulfonylureas or metformin.

Keywords : Repaglinide; Oral antidiabetic agents; Type 2 diabetes mellitus.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License